Volume 9 Supplement 1

Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference


Edited by Diana W Shineman and Howard M Fillit

The conference and the publication of these proceedings were supported by conference grant U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the National Institutes of Health's Office of Rare Diseases. Other sponsors: CoMentis, Eli Lilly and Company, sanofi-aventis, Biogen Idec and The Michael J. Fox Foundation for Parkinson's Research

Drug Discovery for Neurodegeneration Conference. Go to conference site.

Washington, DC, USA

2-3 February 2009

  1. Proceedings

    Characteristics of compounds that cross the blood-brain barrier

    Substances cross the blood-brain barrier (BBB) by a variety of mechanisms. These include transmembrane diffusion, saturable transporters, adsorptive endocytosis, and the extracellular pathways. Here, we focus ...

    William A Banks

    BMC Neurology 2009 9(Suppl 1):S3

    Published on: 12 June 2009